Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- Netflix raises prices in Germany and Austria, Citi comments
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs
July 29, 2024 7:18 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $57.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "BMY's noteworthy outperformance on Friday July 26 (+~11% vs. flat XLV), while it occurred amidst favorable shifts in the broader market macro backdrop, was earned, in our... More
Bristol-Myers Squibb (BMY) stock gains after raising full-year guidance
July 26, 2024 7:51 AM EDTBristol-Myers Squibb (NYSE: BMY) shares rallied more than 5% premarket Friday as the company reported a robust second quarter, surpassing Wall Street's expectations for both earnings and revenue, and raised its full-year guidance.
The pharmaceutical giant posted adjusted earnings per share (EPS) of $2.07, significantly higher than the analyst estimate of $1.64. Revenue for the quarter was also strong at $12.2 billion, beating the consensus estimate of $11.52 billion and marking a 9% increase from the same quarter last year, or an 11% rise adjusting for foreign exchange.
The company's performance was propelled by its Growth Portfolio, which saw... More
